Debt, Initial Public Offering and Medical

Cooley’s 2022 Life Sciences M&A Year in Review

Cooley M&A

JANUARY 25, 2023

But it wasn’t all carve outs and concerned investors – even with the headwinds in the industry and beyond, there were still several traditional public M&A deals involving biotechnology or medical device companies, as large pharmaceutical companies continued to have cash to deploy for acquisitions. Let’s dig in.

M&A

M&A Mergers and Acquisitions Pharmaceutical Collaboration

Cooley’s 2022 Tech M&A Year in Review

Cooley M&A

JANUARY 25, 2023

While direct lenders have historically struggled to compete with the syndicated lending market on price and covenant packages, as the year progressed, sponsors increasingly spurned the syndicated lending market in favor of debt packages arranged solely by direct lenders.

M&A

M&A Mergers and Acquisitions Private Equity Mergers

Investment Banking Today

Cooley’s 2022 Life Sciences M&A Year in Review

Cooley’s 2022 Tech M&A Year in Review

Stay Connected